Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Lysosomal Rare Disorders Research & Treatment Center, Fairfax

Duke University Medical Center, Durham

Allergy Associates of the Palm Beaches, North Palm Beach

USF Health, Pediatric Allergy, Immunology & Rheumatology, St. Petersburg

Ohio Clinical Research Associates, Mayfield Heights

Oklahoma Institute of Allergy and Asthma Clinical Research, Oklahoma City

Discovery Clinical Trials, Dallas

IMMUNOe Research Centers, Centennial